Churchill Capital Corp (CCXI)

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Aksjekursen Churchill Capital Corp XI Class A Ordinary Shares (CCXI) after-hours i dag er 10,17 $, som gjenspeiler en bevegelse på −0,10 % after-hours siden markedet sist stengte. Selskapets markedsverdi er 0,00 $, med et daglig handelsvolum på $ 2,04k aksjer. For investorer som følger kursutviklingen, har Churchill Capital Corp XI Class A Ordinary Shares-aksjen ligget mellom 10,17 $  og 10,17 $ i dag. Den forrige lukkekursen var 10,18 $.

Er du klar til å komme i gang? Følg trinnene nedenfor, eller les vår guide om hvordan kjøpe Churchill Capital Corp aksje på Kraken fra $10.